Table 1 Baseline characteristics between treatment groups
Characteristic | Mepolizumab (n = 36) | Benralizumab (n = 19) | p-value |
|---|---|---|---|
Mean age (range) | 53.8 (33–79) | 59.6 (23–77) | 0.0839 |
Sex | 0.7028 | ||
Female, n (%) | 17 (47) | 10 (53) | |
Male, n (%) | 19 (53) | 9 (47) | |
Smoking history | 0.8406 | ||
Never, n (%) | 23 (64) | 11 (58) | |
Former, n (%) | 7 (19) | 5 (26) | |
Active, n (%) | 3 (8) | 3 (16) | |
No history available, n (%) | 3 (8) | 0 (0) | |
Mean # of comorbidities | 2.3 (0–9) | 3.2 (0–9) | 0.1363 |
Comorbid lung disease | 0.7652 | ||
Yes, n (%) | 10 (28) | 6 (32) | |
No, n (%) | 26 (72) | 13 (68) | |
Anaphylaxis history | 0.0753 | ||
Yes, n (%) | 4 (11) | 6 (32) | |
No, n (%) | 28 (78) | 13 (68) | |
No history available, n (%) | 4 (11) | 0 (0) | |
Non-asthma atopic disease Yes, n (%) | 25 (69) | 14 (74) | 0.6208 |
No, n (%) | 2 (6) | 2 (11) | |
No history available, n (%) | 9 (25) | 3 (16) | |
Food/environmental allergy | 0.4649 | ||
Yes, n (%) | 21 (58) | 11 (58) | |
No, n (%) | 5 (14) | 5 (26) | |
No history available, n (%) | 10 (28) | 2 (11) | |
Family history of atopic disease | 0.2594 | ||
Yes, n (%) | 15 (42) | 12 (63) | |
No, n (%) | 18 (50) | 7 (37) | |
No history available, n (%) | 3 (8) | 0 (0) | |
Mean age of asthma onset (range) | 36.4 (13–59) | 45.8 (13–72) | 0.1800 |
No history available, n (%) | 21 (58) | 8 (42) | |
Mean # of therapies prior to biologic (range) | 3.8 (2–8) | 3.5 (1–5) | 0.6875 |